Lumigan eyelash growth formula
Lumigan (bimatoprost ophthalmic solution 0.03%), also known as Latisse, it contains the active ingredient bimatoprost, which is a type of medicine called a prostaglandin analogue, which has been shown to enhance growth of eyelashes up to 25% longer, 106% thicker and 18% darker in clinical trials and published papers.
Clinically proven results you can see over time. Lumigan is easy to use. It’s a once-a-day treatment you apply topically to the base of your upper eyelashes. Patients in a clinical trial saw results gradually over time (starting at 4 weeks with full results after 16 weeks).
Latisse is a version of a glaucoma drug in eye drop form called Bimatroprost in use since FDA approval in 2001. During that period, eye doctors and their glaucoma patients noticed the hair growth side effect, with longer, lusher eyelashes appearing over time.
At the moment Latisse is licensed in America for eyelash growth. In the UK it is sold as Lumigan 0.3mg/ml but not licensed for cosmetic use.
This is a prescription only medicine and will need a face to face consultation.
Lumigan is not a cosmetic like mascara, it is a drug and you do need a prescription for it. Denise will take a medical history, discuss any concerns to ensure informed consent before a prescription is issued. Tell her if you are planning to have any eye surgery, and please see potential side effects below, you are welcome to a free consultation and Denise will ensure it is safe for you to go ahead with the treatment.
Lumigan used cosmetically is for hypotrichosis
Lumigan solution is a prescription treatment for hypotrichosis used to grow eyelashes, making them longer, thicker and darker. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes.
How is it applied?
- Prep – Wash hands and face with a mild soap and water. Let face and eye area dry completely prior to application and remove contact lenses.
- Lumigan is applied by dabbing it on the upper lash line each night with the sterile applicators supplied. DO NOT APPLY to the lower eyelid. Hair growth may occur in other skin areas that the solution frequently touches. If you develop or experience any eye problems discontinue immediately. The most common side effects after using Lumigan solution are itchy eyes and/or eye redness. If discontinued, lashes will gradually return to their previous appearance.
- One brush stroke is sufficient to cover eyelashes.
Always discard each applicator after one use. Reusing applicators, even just once the next evening, can cause serious problems, such as an eye infection or allergic reaction. It is important that Lumigan is applied carefully as it may promote hair growth on other skin areas.
After 2 months of nightly use, you may begin to see results. After 3-4 months, your dose maybe reduced every 2 days. If you stop using Lumigan, your eyelashes will gradually return to their former state.
How does Lumigan Work?
Lumigan makes eyelash growth possible because of its active ingredient: bimatoprost opthalmic solution. Although the precise mechanism of action is unknown, Lumigan is believed to affect the growth (anagen) phase of the eyelash hair cycle in two ways: first, it increases the length of this phase, and second, it increases the number of hairs in this growth phase.
What are the potential side effects?
According to clinical studies conducted with FDA approval, Latisse eyelash lengthener is safe for most people. However, you may not be a candidate for Latisse if you have certain eye problems (such as uveitis and conjunctivitis), risk of macular oedema, severe allergies or skin infections of the upper eyelids.
Pregnant women should not use it, and nursing women may wish to wait. Because the active ingredient in Latisse lowers intraocular pressure, if you are already using IOP lowering medications for ocular hypertension and/or glaucoma, you must tell your eye doctor before you try Latisse so he or she can monitor your eye pressure closely.
Most study participants had no problems if Latisse accidentally got into their eyes but a few did experience side effects that included dry eyes and eyelid skin darkening.
The side effects that occurred in the largest percentage of participants were eye redness (3.6%) and itchiness (also 3.6%). It was also reported that permanent brown pigmentation of the iris is a potential side effect, but it was not reported as occurring during the study when used for lenthening of the lashes.
When using the product for glaucoma, when dropping it into the eye, there is a small risk 1.9% of discolouration. This risk has been shown to be higher with generic products, but not with Bimatoprost.
Initial treatment pack £90 (lasts 2 months)